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Abstract
Aim. Metastatic disease is the most common liver tumor. Although alternative therapies have been developed for non-
surgical candidates, those therapies lacked ideal testing prior to clinical application because of a paucity of large animal
models. The purpose of the present study was to develop a model for secondary liver tumor in a large animal. Material and
methods. Fibroblasts were isolated from swine ear lobules and then transfected with amphotrophic retroviruses encoding
human or murine genetic material (hTERT, p53DD, cyclinD-1, CDK4R24C, Myc T58A, RasG12V). Transformed cell lines
were finally inoculated subcutaneously (s.c.) into: 1) immunodeficient mice (nude), 2) immunocompetent mice (wild type),
3) immunosuppressed swine (under tacrolimus or corticosteroids), 4) immunocompetent swine, and 5) into the liver and
portal circulation of swine under steroid-based immunosuppression. Results. In the murine model, tumor growth was
evident in 100% of the nude mice (n5), with a peak size of 20 mm (15.2294.5 mm; mean9SD) at the time of sacrifice (3
weeks). Tumor growth was evident in 71% of the wild mice (n21), with a peak size of 7.8 mm (4.1991.1 mm) by the
third week of growth. In the swine model, tumor growth was evident in 75% (3/4 ears; n2) of swine under tacrolimus-
based immunosuppression versus 50% of swine under steroids-based immunosuppression (n2). Tumor growth was slow
in two animals, while in one animal the tumor was larger with a peak growth of 42 mm at 3 weeks. The tumor pattern in the
ear lobules was characterized by slow growth, with a peak size of 68 mm in the immunocompetent swine at 3 weeks. All
tumors were shown to be malignant by histology. In contrast, inoculums of the transformed fibroblast cell line in swine livers
showed no evidence of tumor growth at 3 weeks. Conclusions. Development of a transformed swine fibroblast cell line was
successful, resulting in an in vivo malignant tumor. Cell line inoculums had tumorigenic properties in nude mice, wild-type
mice, and immunosuppressed swine, as judged by uncontrolled cell growth, invasion of surrounding tissue, neoangiogen-
esis, and invasion of normal vasculature, resulting in the formation of tumor nodules. Such properties were not observed in
swine upon inoculation into the liver/portal circulation.
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Introduction
The most common etiology of a liver mass is meta-
static disease, usually from a colorectal primary
tumor. Approximately 75,000 patients per year are
diagnosed with metastatic liver disease in the USA
[1,2]. Only 20% of these patients can have a curative
surgical approach because of the extension of the
malignant process or because of a medical condition
that prohibits surgery [36]. Alternative treatment
modalities have been developed. Ablative therapies
include radiofrequency ablation (RFA), microwave
ablation, and cryoablation. Other therapies for the
control of hepatic tumor growth include chemo-
embolization (TACE) and radio-embolization [5,7
9]. Nevertheless, all techniques have produced incon-
sistent results [3,711]. The purpose of the present
study was to develop a model of secondary tumors of
the liver in a large animal. The swine model offers the
privilege of anatomical, metabolic, and physiological
proximity to the human and, if developed, it may help
us understand the efficacy of the various ablative
modalities under diverse conditions. Development of
a similar animal model by the implantation of human
cell lines into swine livers has been unsuccessful [12].
Here, we describe implantation of a genetically
defined transformed dermal fibroblast cell line from
swine into: (i) nude and wild-type mice, to ensure the
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cell line’s tumorigenic potential, and (ii) immunosup-
pressed and immunocompetent swine, to observe its
biological behavior. Inoculation into the nude mice
and immunosuppressed swine was consistent with
development of tumor growth and neoplastic beha-
vior. Tumors manifested in uncontrolled growth with
invasion of surrounding tissues, neoangiogenesis,
vascular invasion, and tumor thrombus formation.
Inoculation of fibroblast cell line into wild-type mice
and immunocompetent swine was characterized by
slow growth, limited invasion to the surrounding




Dermal fibroblasts were isolated from swine, cultured,
and then transfected with human and murine proto-
oncogenes and mutated tumor suppressor genes, as
previously described by Adam et al. [13]. Briefly,
fibroblasts in culture were transfected with a replica-
tion-deficient retroviral vector encoding for six human
or murine genes: hTERT, cyclin D1, CDK4R24C,
MycT58A, RASG12V, and p53DD. The resulting trans-
formed fibroblasts were then analyzed for the expres-
sion of introduced genes by reverse transcriptase-
polymerase chain reaction (RT-PCR) techniques [13].
Cells with the full expression of the genetic material
were frozen. Inoculums were thawed in a 378C water
bath, washed in Dulbecco’s Modified Eagle Medium
(DMEM) (Invitrogen, Cleveland, Oh., USA), and
cultured in a 75 cm2 culture flask (Becton Dickinson,
Rockville, Md., USA) containing DMEM, 10% fetal
bovine serum (Invitrogen, Cleveland, Oh., USA) and
1% penicillin-streptomycin as media (American Type
Culture Collection, Manassas, Va., USA). Conflu-
ence was reached at 378C, gassed with O2: CO2, 95:
5% by 4 days in a cell incubator (NAPCO CO2 6000;
Cole-Parmer Instrument Company, Vernon Hills, Ill.,
USA). Trypsin-EDTA 0.05% (Invitrogen, Cleveland,
Oh., USA) dissolved in pre-warmed media was added
to the culture flask for 10 min to obtain cells in
suspension. Cells were then centrifuged at 1500 rpm
for 10 min at 48C. Re-suspended cells in 10 ml of
phosphate buffer solution (PBS) (Invitrogen, Cleve-
land, Oh., USA) were counted in triplicate and
recorded as number of cells/ml. An aliquot of the
injected inoculums was saved for: (i) confirmation of
cell concentration administered and (ii) for cell
viability by Trypan Blue exclusion method. Consis-
tently, cell concentration was (1.0390.24)108 cells/
ml and cell viability was 90%.
RT-PCR on cell lines
RT-PCR techniques were conducted on the initial cell
line (6510-6gene) as well as on the cells isolated from
the growing tumor (pig8rt) after inoculation into
swine ear to compare for the tumorigenic expression
at second pass. RNA was isolated using the RNAazole
B reagent (Tel-Test Inc., Friendswood, Tx., USA),
then further purified by the addition of chloroform
and centrifugation. The RNA pellet was reverse-
transcribed using Omniscipt reagents (Qiagen, Valen-
cia, Calif., USA) with oligo dT primers (Invitrogen,
Carlsbad, Calif., USA). Reverse-transcription reac-
tions, incubated at 378C, were set up for each cell
line. The resulting cDNA was used to verify the
absence or presence of expression of specific trans-
genes by PCR amplification with one primer specific
to the transgenes and another specific to a transcribed
region of the pBABE plasmids as noted: 5?-TGGCT
GTGCCACCAAGCATT and 5?-TTTCCACACCT
GGTTGC (hTERT), 5?-GCTCACTCCAGCTACC
TGAA and 5?-ATGCCTTGCAAAATGGCG (p53DD),
5?-AACATGGACCCAAGGCC and 5?-TTCTGCC
TGCTGGGGAG (cyclin D1), 5?-GGTGGTACCT-
GAGATGGA and 5?-TAGCTTGCCAAACCTA-
CAGG (CDK4R24C), 5?-ACGAGCACAAGCTCACC
and 5?-TTTCCACACCTGGTTGC (c-MycT58A) and
5?-GCACGCACTGTGGAATCT and 5?-TAGCTT
GCCAAACCTACAGG ( H-RasG12V). Five micro-
liters of the cDNA was added to the appropriate
transgene specific primer and the PCR reaction
mixture including ddH2O, dNTPs, Redman Taq
buffer, DMSO, and Redman Taq polymerase (Invi-
trogen, Carlsbad, Calif., USA). The reaction was
allowed through a thermocycler with the following
settings: 1 cycle at 94.08C for 5 min followed by 25
cycles at 94.08C for 30 s, 55.08C for 1 min, then
72.08C for 30 s, and one last cycle at 72.08C for
10 min. The amplified cDNA was finally held at 48C
awaiting gel electrophoresis. Twenty-five microliters
of each PCR sample was directly loaded into the wells
of 2% agarose gel and run at 100 volts for optimal
band separation. The gel was then checked for band
expression.
Animal studies
In order to characterize the tumorigenic potential of
the transformed fibroblasts, 1106 transformed cells
in 0.05 ml of PBS were inoculated s.c. into the
abdominal wall of 2030 g xenograft male outbreed
nude mice (n5) (Taconic #NCRNU-M, German-
town, N.Y., USA) and CD57 wild-type male mice
(n21) (Jackson Lab, Bar Harbor, Maine, USA).
The procedures were performed under sterile condi-
tions. The site of injection was inspected daily for
1 week to check for infection or bleed. The growth of
the inoculums was measured weekly in all animals.
Five wild-type mice were killed at time-points 3, 6, 8,
and 12 weeks after injection. All nude mice were killed
at 3 weeks due to rapid growth of the tumor. Mice
were maintained in standard conditions of tempera-
ture, humidity, day/light cycle, and food (Harlan
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Teklad Animal Diets and Bedding, Madison, Wisc.,
USA); water was given ad libitum. Mice were
euthanized by cervical dislocation, and then the
abdominal wall was dissected and fixed in 10%
formaldehyde (Fischer Scientific SF93-4, Florence,
Ky., USA). H&E and Masson’s Trichrome staining
slides were prepared and submitted for morphometric
studies
Studies in swine (Yorkshire Swine, Pine View
Farms, Valley City, Oh., USA) were performed by
inoculation of the transformed fibroblast cell line
into the ear lobules and also the liver/portal circula-
tion. 1108 cells suspended in 1 ml of PBS were
inoculated s.c. into three groups of swine: (i) tacro-
limus-based immunosuppressed animals (n2), (ii)
steroid-based immunosuppressed animals (n2),
and (iii) immunocompetent animals (n2). Tacroli-
mus (Prograf†, Novartis, N.J., USA) was given orally
every 12 h at a dose of 0.2 mg/kg/day. Treatment
started 1 week prior to cell line inoculation. Trough
levels in blood were checked twice per week by ELISA
(Chemistry Laboratories, University Hospitals-Case
Medical Center) (Figure 1). A second group of swine
was provided with a single intravenous dose of 250 mg
of methyl-prednisolone (Solu-Medrol 125 mg/2 ml,
UPJohn, Kalamazoo, Mich., USA) at the time of cell
implantation.
Swine were sedated with Ketamine 20 mg/kg prior
to general anesthesia. A mixture of Isofluorane: O2
1:99% was administered while the animals underwent
a 4 cm midline incision under sterile conditions. 1
108 cells were needle-injected into three different sites
in the right liver and intravenously into the portal
circulation. Hepatic sites of injection were tagged by
non-resorbable suture (SurgiPro5:0’s U.S. Surgical
Corp., New Haven, Ct., USA). Tumor growth in
swine was monitored by follow-up of ear lobule
inoculums and weekly liver ultrasound. At 3 weeks,
liver tissue and ear lobules were collected, fixed
with 10% formaldehyde and H&E, and Masson’s
Trichrome stained slides were prepared. The sedated
swine were then euthanized by an IV sodium pento-
barbital overdose. All animal protocols were approved
by the Institutional Animal Care and Use Committee
(IACUC) according to Case Western Reserve Uni-
versity guidelines for animal research.
Histopathological evaluation
Blinded slides were assessed by three authors for
evidence of lymphocytic infiltration, extent of central
necrosis, neoangiogenesis, and tumor invasion. Three
digital records from representative areas were saved
from each animal in each group using a Digi3 Digital
Binocular Microscope (International Falls, Minn.,
USA). Digital images were printed and then blind
graded for lymphocytic infiltration (grade 0B10
lymphocytes per field, grade 11030 lymphocytes
per field, grade 230 lymphocytes per field; 40
magnification), extent of central necrosis (grade 0
no tumor necrosis, grade 1B25% tumor necrosis,
grade 22550% tumor necrosis, grade 350%
tumor necrosis; 20 magnification), neoangiogenesis
(grade 0no evidence of new vessel formation within
the tumor, grade 155 vessels per field within the
tumor, grade 25 vessels per field within the
tumor; 40 magnification), and tumor invasion
(grade 0no tumor invasion, grade 1tumor inva-
sion to surrounded tissues, and grade 2tumor
invasion to native vessels with tumor thrombus
formation; 40 magnification) (Figure 2). For pur-
poses of lymphocyte infiltration and neoangiogenesis
evaluation, slides were submitted for immunohisto-
chemical staining for CD3 and CD34 cell surface
proteins; CD3 is a receptor specific to all T lympho-
cytes, while CD34 is a hematopoeitic stem cell marker
indicative of neoangiogenesis. All immunohistochem-
ical stains where conducted in the clinical laboratories
at the University Hospitals Case Medical Center
(Cleveland, Oh., USA) with the use of a horseradish
peroxidase labeled system, Envision (Dako, Car-
pinteria, Calif., USA). This method uses an unlabeled
primary polyclonal antibody to CD3 (ref. #A0452,
Dakocytomation, Carpinteria, Calif., USA) and a
monoclonal antibody to CD34 (ref. # M7165,
Dakocytomation, Carpinteria, Calif., USA), coupled
to a secondary horseradish peroxidase labeled poly-
mer conjugated to antimouse immunoglobulins. Po-
sitive and negative controls were performed
simultaneously.
Statistical analysis
Mean values are presented with standard deviations
(mean9SD). Student’s t-test (two-tailed) was used to
calculate the significance of difference in the mean
values (http://www.physics.csbsju.edu) and Fisher’s
exact test to calculate the significance of categorical
percentage data differences (http://www.exactoid.
com/fisher). A p-value B0.05 was considered statis-
tically significant.
Figure 1. Tacrolimus levels in swine serum: Through levels of
tacrolimus in the serum of swine before and after implantation of
fibroblast cell line inoculum into ear lobules.
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Results
RT-PCR of the cell lines
Transformed fibroblasts isolated from the ear inocu-
lums expressed genes including p53DD, cyclin D1,
CDK4R24C, c-MycT58A, and H-RasG12V, but not
hTERT when compared to the mother cell line. The
hTERT RNA was slightly degraded in the trans-
formed fibroblast 6510-6 gene line, and does not
appear to be expressed in the cells extracted from the
pig8rt tumor growth (Figure 3).
Characterization of the tumor in the murine model: Nude
versus wild
Tumor growth was documented in 100% (5/5) of the
nude mice versus 71% (15/21) of the wild CD57 mice
at 3 weeks (pB0.02; Student’s t-test). Peak tumor
growth in nude mice was evident at 3 weeks, when
most of the mice were showing signs of sickness,
reaching a mean size of 15.2294.5 mm, at the time of
sacrifice (Figure 4). The biological behavior of the
tumor was characterized by uncontrolled prolifera-
tion, dense angiogenesis, and local invasion. Tumors
in the nude mice had a pseudo-capsule formed by
connective tissue; some extended beyond the s.c.
layer, invading and adhering into the adjacent perito-
neal layer and reaching the bowel. In a 3-week span,
tumors progressed to outgrow their vascular supply,
resulting in a central necrotic zone. In contrast, wild-
type mice showed slow growth of the inoculums.
Tumor growth was 4.1991.1 mm at 3 weeks after
implantation. After 3 weeks, most tumors became
non-palpable, though they remained histologically
detectable in 60% of the immunocompetent rodents
(Figure 4).
Figure 2. Histological grading system for fibroblast cell line growth: Histologic findings of s.c. inoculums into the abdominal wall of nude
and wild mice, and into the ear lobules of immunosuppressed and immune intact swine. Lymphocyte infiltration assessed by anti-CD3
immunostaining is graded into grade 0B10 lymphocytes per field, grade 11030 lymphocytes per field, grade 230 lymphocytes at
high power field; 40 magnification. Extent of central necrosis is rated by grade 0no tumor necrosis, grade 1B25% tumor necrosis,
grade 22550% tumor necrosis; 20 magnification. Neoangiogenesis confirmed by anti-CD34 stained slides is graded 0 if there is no
evidence of new vessel formation within the tumor, grade 155 vessels, grade 2]5 vessels per high-power field; 40 magnification.
Tumor invasion is defined by grade 0 if the tumor is confined to its capsule, grade 1tumor invasion to surrounded tissues, and grade
2tumor invasion to native vessels with tumor thrombus formation at high-power field; 40 magnification.
Figure 3. The expression of mutations of genetically induced
fibroblast cell line before and after inoculation by RT-PCR: the
expression of H-RasG12V, c-mycT58A, CDK4R24C, cyclin D1,
p53DD, and hTERT in the primary pig fibroblast cell line (6510)
is compared to the initial transformed pig fibroblast cell line (6510-
6 gene), and to the cell line derived from the tumor removed from
the ear of the injected swine (swine2rt). The water lane served as a
control to ensure that there was no reagent contamination giving us
false-positive bands. The beta-tubulin served as a loading control
ensuring that the RNA extract from the cells was not degraded
and was isolated properly. The tumorigenic expression appears
similar in the initial fibroblast cell line and the post-inoculation cell
line except for the expression of hTERT, which did not express in
the tumor isolate.
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Cell line behavior in the swine model: immunosupressed
(tacrolimus and steroids based) versus immunocompetent
In swine, the transformed fibroblast cell line had a
different pattern of growth depending on the degree of
immunosuppression and site of the inoculum. Tumor
growth was evident in 75% of ears lobules in the
tacrolimus-based immunosuppressed swine, in 50%
of ear lobules in the steroid-based immunosuppressed
swine, and in 25% of ear lobules in the immunocom-
petent animals. Tumor growth was evident in the
tacrolimus-exposed ear lobules, with a peak growth of
42 mm at 3 weeks. In contrast, tumor growth was
slower in the ear lobules of steroid-based immuno-
suppressed swine (6.1793.04 mm) and in ear lobules
of immunocompetent swine (8 mm). The biological
behavior of the cell line growth was similar in both
immunosuppressed groups of swine; we observed
increased cellular proliferation, with regional invasion
into the deeper cartilaginous and muscle layers,
neoangiogenesis, invasion of native vessels with tumor
thrombus formation (Figure 4). The tumor growth
pattern in the immunocompetent group was charac-
terized as poor, with a lack of neoangiogenesis and
formation of a pseudo-capsule of dense connective
tissue with various degrees of lymphocyte infiltration.
Upon inoculation of the tumor cell line into the liver
and portal circulation, no tumor growth could be
detected. The development of a fibrotic process with
various degrees of inflammation was noted without
any sign of malignant growth.
Grading of the cell line potential for lymphocytic
infiltration, necrosis, neoangiogenesis, and tumor invasion
We observed a different lymphocytic response and a
superior potential for necrosis, neoangiogenesis, and
tumor invasion in the nude mice compared to the
wild-type mice (Figure 4). While the nude mice
lacked a lymphocytic response (athymic mice), the
wild type presented a robust immune reaction (2696
lymphocytes per high-power field; 40 magnifica-
tion) (Student’s t-test; p-value B0.001). Necrosis was
also observed in 4/5 of the nude mice but not in any of
the wild-type mice. For the neoangiogenic potential,
nude mice showed more than 5 vessels per high-power
field (grade 2) versus no evidence for new vessel
formation in the wild-type mice (Student’s t-test;
p-value B0.009). Tumor in 2/5 of the nude mice
extended into the peritoneal space, while in only 2/21
of the wild-type mice did the tumor extend beyond
the pseudo-capsule and into the stomach (Fisher
exact test, 2-tailed; p-value B0.15).
Tumor growth in the swine model shared a similar
lymphocytic infiltration despite the varying degrees of
immunosuppression. In addition, tumors in the swine
presented no evidence of necrosis. Tacrolimus-treated
animals differed in both the observed neoangiogenesis
and in the degree of tumor invasion compared to the
steroid-immunosuppressed and immunocompetent
swine. The tumor in swine on tacrolimus demon-
strated neoangiogenesis and vascular invasion. This
was not observed in the immunocompetent or steroid-
treated animals (Figure 4).
Discussion
The purpose of these studies was to develop a model
of secondary liver tumor using a genetically defined
allogenic fibroblast cell line from swine. A trans-
formed fibroblast cell line was grown in culture
[13]. S.c. inoculums of the cell line showed typical
malignant behavior in nude and wild-type mice. A
Figure 4. Histologic grading of the genetically defined tumorigenic swine cell line. Cell lines were inoculated into the abdominal wall of
nude and immunocompetent mice as well as into ear lobules of swine immunosuppressed with tacrolimus, with corticosteroids, or that were
immunocompetent. Inoculums were evaluated at 3 weeks in all animals.
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similar pattern of growth was observed upon inocula-
tion into ear lobules of tacrolimus-immunosuppressed
swine, less so when animals were treated with steroids,
and to an even lesser extent in ear lobules of immuno-
competent swine. No malignant growth resulted from
direct inoculation of the transformed cells into the
liver parenchyma or through the portal circulation in
steroid-treated swine.
A model of secondary liver tumors in a large animal
should ideally express specific characteristics. The
animal model must resemble the human scenario in
terms of size, anatomy, and physiology. The tumor
should be easy to develop and reproduce, with a
highly predictable pattern of growth. Finally, the
process of reproducing a tumor model in a large
animal must be financially accessible and cost effec-
tive. In our case, we were successful at developing a
reliable and reproducible s.c. fibroblast tumor model
only when swine were tacrolimus-treated. Tacrolimus
(FK506) acts directly on the T-lymphocytes by
binding to the FK-binding protein (FKBP) and
competitively inhibiting calcineurin, a phosphatase
that is active only when bound to calcium and
calmodulin [14]. As a result, T cells do not produce
IL-2, which is necessary for full T-cell activation [14].
Tacrolimus-based immunosuppression of swine, how-
ever, raises logistic and financial challenges. Animals
must ingest the required dose every 12 h. Some
authors have achieved adequate levels by placement
of a percutaneous gastrostomy tube [15]. In addition,
the cost of this immunosuppressant regimen lies in the
range of 500 US dollars per week with an additional
150 dollars per blood level measurement [16]. To
limit the experimental cost with no compromise to
the higher aim, tacrolimus was substituted for corti-
costeroids. Corticosteroids exert their effects on cells
involved in immune and inflammatory responses
primarily by modulating the transcription of a large
number of genes, subsequently affecting the function
of both T and B cells, and macrophages [1719]. In
addition, corticosteroids have been implicated in
promoting apoptosis of T lymphocytes [20]. Swine
were then treated with a single injection of methyl-
prednisolone at the time of inoculation, at a dose of
15 mg/kg and a total treatment cost well below 50 US
dollars. However, tumor growth was achieved in only
50% of ear lobule inoculums and in none of the swine
liver inoculums.
The transformed fibroblast cell line revealed malig-
nant behavior ranging in severity depending on the
species, the animal’s immune status, and the site of
inoculation. The inoculums were more successful in
the murine model versus the swine. The tumor not
only grew in a higher percentage of either nude or
wild-type mice, but also peaked at a higher rate,
reaching proportionally larger sizes despite the num-
ber of cells in the inoculums relative to the animal
size. The tumor reached a peak of 20 mm in the nude
mice from an initial inoculum of 106 cells, and hardly
8 mm in the steroid-treated swine from an initial
inoculum of 108 cells at 3 weeks. Furthermore, tumor
aggressiveness was markedly stronger in the immuno-
compromised animals compared to the immunocom-
petent animals. Tumors grew at a faster rate replacing
the abdominal wall of the nude mice with invasion of
the abdominal cavity. Tumor biological behavior was
altered by the immune regimen; the inoculums grew
in proportion to the immune-suppression status of
the animal (i.e. tacrolimus 42 mm versus steroids
8.32 mm, versus immunocompetent 6 mm). As to
how the immune response differed upon inoculation
into the liver versus the ear lobules remains a matter
of speculation. Perhaps the high perfusion rate to the
liver, as well as the presence of Kupffer cells, provided
this organ with more robust defense against the
nesting of tested malignant cells relative to the s.c.
area of the ear lobule or the abdominal wall [21].
In response to an antigenic encounter, the immune
system generally provides both a non-specific and a
specific response. When an antigen crosses a defense
barrier such as the skin, a non-specific immune
response is elicited, resulting in an inflammatory
exudate with activation of macrophages, neutrophils,
and mast cells. This initial response is clinically
manifested by erythema, edema, hyperthermia, and
pain. Once an antigen is processed and presented to
lymphocytes by class 1 or 2 MHC receptor-mediated
mechanisms, it promotes a Th1 or Th2 response
depending on the antigen type, be it a tumor cell, a
non-self cell, or even both. Activation of CD4 and
CD8 T cells is then expressed by the release of
cytokines and activation of natural killer (NK) cells,
among other cells, which are involved in tumor
destruction [22]. Acute cellular rejection of alloanti-
genic cells is also characterized by strong lymphocyte
infiltration with destruction of the graft. A decrease in
the tumor size noted in the immunocompetent
models by the second week may be partly explained
by the disappearance of local edema as the inflam-
matory reaction subsided, and partly by the launching
of a tumor-specific immune response. At 3 weeks
from inoculation, tumor growth persisted in only 60%
of the immunocompetent mice, while 100% of the
nude mice tumors progressed at constantly increasing
rates.
The results of the present study must be seen in
light of its limitations. A population of more than two
swine undergoing tacrolimus treatment would have
empowered the predictability of tumor growth. Liver
inoculation of tacrolimus-treated swine should also
have been attempted. However, survival of swine
under tacrolimus treatment was greatly compromised
by the increased incidence of acquired infections; one
of the swine on tacrolimus died of diarrhea just prior
to the end of the third week. The rise in infection
would then be elicited by the absence of immune
defenses combined with the animal’s habits and
behavior in the setting of a surgical skin site. No signs
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of infection in the wound or peritoneum were
observed in the present studies.
To achieve the ideal model of secondary liver tumor
in swine, future directions will include genetic,
technical, and immune-related considerations.
Further genetic manipulations could enhance the
malignant properties of the cell line. Tumor cells
may then overcome the immune boundaries of the
liver [13,23]. Other techniques for cell line inocula-
tion into the liver could prove fruitful. The VX2
tumor model is an anaplastic squamous-carcinoma
cell line that grows in the livers of wild rabbits. Tumor
cells are initially inoculated s.c. or intramuscularly,
with the resulting solid tumor being sectioned and
implanted into the liver [24]. Such a technique may
prove successful in our fibroblast cell line. Finally, as
the role of immunosuppression has been clearly
established in the development of this tumor, a
balance in the degree of immune control should be
attained to ensure tumor growth while maintaining
survival of the animal until study completion and at
reasonable cost. In this perspective, we may consider
the use of immunosuppressants such as Alemtuzumab
(Campath-1), a monoclonal antibody to the CD-52
lymphocyte receptor. It depletes T populations up to
a year. To the best of our knowledge, however, this
approach has not been explored in swine [25]. Finally,
the immune response of allogenic cells could be
potentially reduced by the inoculation of transformed
cell lines into genetically identical cloned swine; a
process that may increase the experimental cost.
In conclusion, the results of these studies demon-
strate the development of a secondary tumor model in
a large animal by s.c. inoculation of a genetically
manipulated fibroblast cell line into immunocompro-
mised swine. The tumor in the immunocompetent
animal is characterized by slow growth and poor
potential for neoangiogenesis, regional, and vascular
invasion. The malignant potential of the fibroblast cell
line is greatly enhanced at deeper levels of immuno-
suppression. Thus, future efforts by further genetic
manipulation to the fibroblast cell line, as well as
refinement of the inoculum administration techni-
ques, stand to amplify the aggressive potential of the
transformed cells, thus reaching a faster and a more
secure chance of tumor growth.
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